Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy

Abstract

Circulating miRNAs are proposed as a biomarker of heart disease. This study evaluated whether circulating miRNAs could be used as a biomarker for childhood dilated cardiomyopathy (CDCM). A total of 28 participants were enrolled in a discovery set, including patients with CDCM (n = 16) and healthy children (n = 12). The cardiac function of patients with CDCM was characterized by echocardiography and serum miRNA profiles of all participants were assessed by miRNA sequencing. After miRNA profiling, we quantitatively confirmed 148 regulated miRNAs in patients with CDCM compared with healthy subjects, and none were downregulated. Validation of candidate miRNAs was assessed by quantitative real-time polymerase chain reaction in other patients with CDCM (n = 30) and healthy controls (n = 16). A unique signature comprising mir-142-5p, mir-143-3p, mir-27b-3p, and mir-126-3p differentiated patients with CDCM from healthy subjects. Importantly, we observed an increase in mir-126-3p or let-7g in parallel with a robust decrease in the ejection fraction in patients with CDCM, which could differentiate heart failure patients from non-heart failure patients with CDCM. Moreover, mir-126-3p and let-7g were significantly negatively associated with the left ventricular ejection fraction. This study shows that a signature of four serum miRNAs may be a potential biomarker for diagnosing CDCM and assessing heart failure.

Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy

“…Platelet extracellular vesicles exhibit upregulated miR-142-5p, which is involved in vascular and metabolic disease [21]. miR-142 is suppressed in a hypertrophic heart model and human cardiomyopathic hearts [22]. miR-142-5p was upregulated in heart failure patients undergoing implantation of a left ventricular assisting device.…”

Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology

“…The circulating profile of miR-27b-3p, miR-126-3p, miR-142-5p, and miR-143-3p seems to discriminate between patients with DCM from healthy subjects. 66 Interestingly, Miyamoto et al 67 identified specific serum miR-NAs that can be used for risk stratification in children with DCM. Using an array for 754 miRNAs and RT-qPCR validation, the authors found a differential expression profile of miR-155, miR-636, miR-639, and miR-646 in patients who were transplanted or died compared with patients who recovered their ventricular function.…”

For Novel Disease Diagnostic Markers in Blood RNA

“…The cardiac function of patients with childhood dilated cardiomyopathy (CDCM) was characterized by echocardiography and serum miRNA profiles of all participants were assessed by miRNA sequencing. As a result, a unique signature comprising mir-142-5p, mir-143-3p, mir-27b-3p, and mir-126-3p differentiated patients with CDCM from healthy subjects [5]. Thus, circulating microRNAs (C-miRNAs) have emerged as measurable biomarkers (liquid biopsies) for not only various cancer detection but other diseases.…”